Fig. 2: In vivo characterization of HuMab006-11.
From: Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus
a Schematic representation of human liver chimeric mouse development. b Production of hALB in all mice was measured at ~5 mg/mL. c Schematic diagram indicative of antibody injection (HuMab006-11 (IgG1), virus inoculation, and serum sampling for prophylactic treatment. Weekly quantification of d. HBV DNA (statistical analysis between mAb006-11 and isotype Control mAb was performed using a t-test) and e HBsAg production (Statistical analysis between mAb006-11 and Control mAb was performed using an F-test) in mice injected with isotype control mAb, HBIG, or HuMAb006-11 one day before HBV inoculation of up to 35 dpi. f Histological analysis of mouse liver sections stained with hFAH, HBcAg, and H&E. g The schematic diagram for therapeutic treatment is indicative of antibody injection, virus inoculation, and serum sampling. Weekly quantification of h. HBV DNA (statistically analysis between HuMAb006-11 and HBIG was performed using an F-test) and i HBsAg production (statistically analysis between mAb006-11 and HBIG was performed using an F-test) in mice injected with isotype control mAb, HBIG, or HuMAb006-11 at 42 dpi following the establishment of HBV infection. Further quantification was performed at 1–4 days post-antibody injection intervals for 15 days. j Histological analysis of mouse liver sections stained with hFAH, HBcAg, and H&E. Scale bars for hFAH, HBcAg, and H&E are 100 µM. The scale bar for red box images is 50 µM. Each group composed by n = 3 mice *p < 0.05, **p < 0.005, ***p < 0.0005.
